EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 11
Issue: 2
214-223
Year: 2024

REVIEW ON: INTERLEUKIN-6 IN RHEUMATOID ARTHRITIS

Sounak Majee and Bapi Paul*

India.

***Corresponding Author: Bapi Paul**
India.

Article Received on 08/12/2023 **Article Revised on 28/12/2023** **Article Accepted on 18/01/2024**

ABSTRACT
In 1929 rheumatoid arthritis (RA) patients frequently prioritized pain as a major symptom and it was a prevalent disease among Egyptians. RA treatment is expected to include pain management as part of inflammation control, intuitively, RA-related pain is frequently regarded as a natural consequence of peripheral inflammation. However, there can be a low correlation between objective measures of inflammation and pain in RA patients. Systemic inflammatory disease's pathogenesis relies heavily on the potent pro-inflammatory interleukin (IL)-6. Since IL-6 is necessary for both the destruction of joints and the manifestation of the disease throughout the body, it seems like a promising strategy to target this pathway in RA. To this point, data on efficacy show that Interleukin-6 inhibition performs better than placebo, conventional anti-rheumatic drugs like methotrexate, and TNF inhibition. In addition, even though the safety profile differs significantly from that of TNF inhibition (such as hyperlipidemia and neutropenia), these safety concerns have not been found to cause clinically significant side effects as of yet. Infection and malignancy rates, among other safety parameters, were found to be comparable between TNF inhibition and IL-6 inhibition. The biology and clinical applications of IL-6 inhibition in the treatment of rheumatoid arthritis are examined in this review.

KEYWORDS: Rheumatoid arthritis, Osteoarthritis, DMARD, Tumor necrosis factor-alpha Inhibitors, IL-6 inhibitors, Autoimmunity, Cytokine Receptor, Inflammation, Interleukin-1, Interleukin-17, Interleukin-10, and GM-CSF.

INTRODUCTION

A constant, immune system infection, rheumatoid joint inflammation (RA) influences around 1% of the total populace. RA is a long-lasting inflammatory condition that mostly impacts the joint and it is characterized by pain and swelling in the synovial joint tissue, as well as the potential other organ systems, such as the cardiovascular, pulmonary, and skeletal systems, are involved. both directly and indirectly. Additionally, it frequently has a significant psychological impact.[1] The disease's pathogenesis is driven by the inflammatory cells and mediators that are the targets of the disease-modifying agents used to treat RA.[2]

The primary and often crippling symptom of RA is pain. The reduction of pain has repeatedly been ranked as the health outcome with the highest importance for RA patients. Several cytokines have been found to affect RA pain, including the type of previously described cytokines.[3,4] One of the main cytokines implicated in the pathophysiology of rheumatoid arthritis is IL-6. Interleukin-6 is a cytokine that plays a key function in the immune response and inflammation.[5] Although it is widely believed that cytokine-driven joint inflammation is Although inflammation is the major source of pain in RA, new research suggests that non-inflammatory initiators such as am neuropeptides and cytokines may also influence pain by having a direct impact on the neurological system.[6] Especially, points to a critical role for IL-6, which may influence pain associated with RA via a variety of pathways in addition to indirectly through joint inflammation.[6,7]

The synovial tissue contains a variety of cells that can produce IL-6, including fibroblasts, macrophages, and T lymphocytes. There is evidence that IL-6 contributes to the pathophysiology of RA by driving synovial inflammation, joint degeneration, and systemic symptoms of the illness.[8] IL-6 levels are higher in the synovial fluid and serum of RA patients. IL-6 increases inflammation by stimulating immune cells including T cells and B cells and promoting the release of other pro-inflammatory cytokines like TNF-, IL-1, and IL-17.[9,10]

The important use of IL-6 inhibitors, such as tocilizumab, in the treatment of RA, emphasizes the significance of IL-6 in the disease. A monoclonal antibody called tocilizumab binds to IL-6 receptors and

stops IL-6 from connecting to and activating immune cells. In rheumatoid arthritis-affected patients who have not responded to previous medications, such as TNF inhibitors, tocilizumab has been proven to reduce inflammation and enhance clinical outcomes.[11]

1. ARTHRITIS

The most common signs of arthritis are joint pain and stiffness, which typically get worse with age. Arthritis is characterized by swelling and tenderness in one or more joints. Rheumatoid arthritis and osteoarthritis are the most common forms of arthritis.[12]

The breakdown of cartilage, the tough, slippery tissue that covers the ends of bones, is caused by osteoarthritis. The immune system attacks the joints from the inside in rheumatoid arthritis.

In the public health sector, arthritis is a catch-all word for over 100 rheumatic disorders that damage joints, the tissues surrounding the joints, and other connective tissue.

2. RHEUMATOID ARTHRITIS

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that impacts the joints. It's looking like an advanced symmetric joint inflammation leading to cartilage damage, bone erosion, and disability.[12] While just a few joints are afflicted at first, numerous joints are impacted later on, and extraarticular symptoms are typical.[13] With a frequency ranging from 0.4% to 1.3% of the population depending on both sexes (women are affected two to three times more often than men), age (there is the incidence to the prevalence of new RA diagnoses peaks in the sixth decade of life), and a patient collective was analyzed (RA frequency increases from south to north and is greater in urban than rural areas) [14,15], RA is one of the most common chronic inflammatory illnesses which are affected to the joint.[16]

Clinically, the symptoms of RA differ significantly between early-stage RA and poorly treated later stages of the illness. RA is characterized by generalized illness symptoms such as tiredness, flu-like symptoms, swollenness, and morning stiffness, as well as raised C-reactive protein (CRP) values and an increased erythrocyte sedimentation rate (ESR).[17] The presence of serious systemic indicators such as pleural effusions, lung nodules, interstitial lung disease, lymphomas, vasculitis in small or medium-sized arteries, atherosclerosis, rheumatologic abnormalities (such as anemia, leukopenia, neutropenia, eosinophilia, thrombocytopenia, or thrombocytosis), joint malalignment, loss of range of motion, bone erosion.[13,15,18]

3. CYTOKINES IN RHEUMATOID ARTHRITIS

Cytokines are crucial protein mediators involved in various biological processes, including cell growth, activation, inflammation, immunity, and differentiation. Their role in RA pathogenesis has led to the development of novel therapeutics targeting specific cytokines with both organic and small atoms,[20] in which there is ongoing aggravation, with fibrosis and the possible obliteration of ligament and bone. Even though these biological agents are commonly used to treat rheumatoid arthritis, most doctors only prescribe them after conventional treatment has failed. Cytokines like IL-6 play an important role in inflammatory responses.[20]

Cytokine plays a crucial role in RA pathogenesis, regulating cellular phenotype, localization, activation status, and longevity. Successful targeting of these cytokines with biological therapies has demonstrated the critical role of TNF and IL-6 in RA.[21] Cytokine classification is essential for understanding the progression of RA, driving tissue components, and potentially aiding in hard-headed illness. Key cytokines like IL-17 and GM-CSF are gaining attention. Cytokine interactions are evident in RA pathobiology (foundational and synovial) and disease stages (early and late).[22]

There are numerous cytokines associated with RA pathogenesis. In this survey, we center our advantage around not many that are focal and designated in RA treatment like IL-6, TNF, IL-1, IL-17, IL-10, and GM-CSF.

INTERLEUKIN

6 (IL-6) was first identified and cloned by Kishimoto and Hirano in 1986 as a cytokine that regulates B-cell differentiation.[23] It is an interleukin that acts as both a pro- inflammatory and an anti-inflammatory myokine and also stimulates osteoclast formation. IL-6 cytokine plays a prominent role in the coordinated systemic host defense response to injury. It is an interleukin that acts as both a pro-inflammatory and an anti-inflammatory myokine and also stimulates osteoclast formation.

IL-6 is a cytokine with pleiotropic and redundant action, belonging to the cytokine family of cytokines like IL-6, IL-11, IL-27, IL-31, and others. It is rapidly generated by macrophages in response to infections or inflammation-related damage.[24] and serves a protective function by eliminating infectious agents and mending wounded tissue via activation of the acute phase and immunological responses.

IL-6 is generated by a variety of cells, including T cells, B cells, monocytes, activated synovial fibroblasts, keratinocytes, endothelial cells, mesangial cells, adipocytes, and certain tumor cells.[25] IL-6, a monomeric protein, is produced by various cell types and plays a crucial role in both antigen and inflammatory responses. It attaches to a receptor complex consisting of subunits (IL-6R) and gp130. IL-6 is essential for hepatocyte production of C-reactive protein and fibrinogen.[26]

IL-6 is made out of 184 amino acids and structures as a

four-helix protein. An a-chain of glycoprotein 130 (gp130) and two chains make up the IL-6 receptor (IL-6R).[27] IL-6 in RA patients' synovial membrane and joint fluid samples contributes to pannus development and local manifestations, as it requires enlistment and relationship with the gp130 protein for signal transduction.[28] IL-6 activates various cell types, including synovial fibroblasts and immune system cells. It may transform naive lymphocytes into Th17 lymphocytes, affecting the local inflammatory process, and synovial-produced IL-17.[29]

4. IL-6 Signaling

The IL-6 receptor is a member of the JAK/STATs signal transduction pathway-associated cytokine class I receptor family.[30] To regulate target gene transcription, Janus kinase activation causes STAT phosphorylation, dimerization, and translocation to the nucleus.[30] IL-6 and IL-6R are signaling systems with receptor chains and signaling molecules, including IL-6R in two forms (80 kDa transmembrane and 50-55 kDa soluble), and a 130 kDa gp130 transducer chain.[31] SIL-6R is found in serum and interstitial fluid, with transmembrane IL-6R expression restricted to hepatocytes and leukocytes in inflammatory diseases. It initiates the homodimerization of IL-6R in gp130 chains.[31]

The IL-6R complex consists of IL6, IL-6R, and gp130 particles, with the gp130 signaling chain shared by cytokines, including leukemia suppressor factor, despite IL-6R being a unique binding receptor.[32] IL-6 and IL-6R display biological activity by attaching to its receptor, IL-6R. They have no affinity for gp130 but bind and activate gp130, causing dimerization and intracellular signaling (Fig. 1).[33,34] Janus kinases (JAKs) are the initial step in intracellular signaling, activating the cytoplasmic tail of gp130. Auto-phosphorylation of JAKs causes cytoplasmic phosphorylation on five tyrosine residues. Src-homology 2-containing protein tyrosine phosphatase 2 (SHP2) docks at the membrane-proximal tyrosine, activating two STAT- independent pathways triggered by IL-6: the MAPK and PI3 K pathways. STAT3 and STAT1 are activated through phosphorylation and dimerization, triggering target gene transcription. IL-6 signaling also stimulates Src-family kinase (SFK)-dependent signaling, likely activating transcriptional regulators like YES-associated protein (YAP) and the JAK/STAT pathway.[35]

IL-6R can be cleaved from cell membranes by ADAM17, producing soluble IL-6R (sIL-6R), extending IL-6's biological activity beyond the cell.[36] Soluble IL-6R binds to IL-6, initiating intracellular signaling called "trans-signaling" and IL-6's membrane-bound mIL-6R signaling. T cells respond to IL-6 in the absence of mIL-6R expression through a novel mechanism called "trans-presentation".[37] Dendritic cells introduce layer-bound IL-6Rα in complex with IL-6, which is detected by gp130 atoms on immune system microorganisms. Pathogenic T-helper 17 cells require IL-6 trans-presentation, which can be blocked by anti-IL-6R antibodies. This discovery highlights the IL-6 pathway's intricacy and calls for careful consideration in developing innovative treatment approaches. Further study in human cells is needed to understand this complex pathway.



Figure 1: IL-6 has pleiotropic action. IL-6 functions as a BSF-2, causing activated B cells to produce antibodies. When coupled with TGF-b, IL-6 preferentially enhances Th17 cell differentiation while inhibiting TGF-b-induced Treg formation.

5. IL-6 AND IL-6 RECEPTOR PATHWAY

IL-6 and IL-6R are signaling systems with two receptor chains and downstream molecules. IL-6R consists of an 80 kDa transmembrane IL-6R, 50-55 kDa soluble IL-6R (SIL-6R), and a 130 kDa gp130 signal transducer chain.[38] SIL-6R, or transmembrane IL-6R, is produced by proteolytic cleavage of the proximal membrane unit or alternative splicing of IL-6R gene 48892 A/C (rs8192284). This results in a functional amino acid change, affecting serum levels. In some inflammatory diseases, IL-6R expression is restricted to cells, while SIL-6R is present in serum and interstitial fluid. The IL-6 cytokine receptor complex triggers the homodimerization of IL-6R gp130 chains, affecting the downstream signal cascade.[39]

The complex of IL-6 and transmembrane IL-6R, IL-6R, associates with the signal- transducing molecule gp130, triggering the activation of subsequent signaling events in target cells via Janus kinase (JAK).[40,41] The classic signaling pathway involves activating gp130 on various cells, while transmembrane IL-6R is only expressed on hepatocytes and leukocytes. Serum contains a soluble form of IL-6R called sIL6R, which has a similar affinity to IL-6. The IL-6 and sIL6R complex can bind to gp130, activating the trans-signaling process. This process is proinflammatory, while traditional signaling is required for regenerative or anti-inflammatory functions.[42] The phosphorylation of JAK, a member of the tyrosine kinase family, further triggers the activation of STAT 3 and the hyperphosphorylation of mitogen-activated protein kinases (MAPKs).[43] The first needs the Phosphorylation of gp130 at tyrosine 759 (Y759) and Y767, Y814, Y904, or Y915 in the YXXQ motif is necessary for STAT3 to activate cell growth and differentiation.[44,45]

6.1. The effect of IL-6 In RA

Both sIL-6R and IL-6 are abundant in the synovial joint and sera of RA patients. There is a correlation between IL-6 and sIL-6R levels, disease activity[46], and joint damage.[47,48] In the development of plasma cells, IL-6 plays a significant role. Increased serum IgM and IgG rheumatoid factors and antibodies to citrullinated peptides cause the initial acute inflammatory reaction in RA patients' synovial fluid. Autoantibodies like rheumatoid factor can be produced by the production of IL-6 through a mechanism thought to involve B-cell differentiation and formation.[49]

6.1.1. Joint inflammation and destruction

- **Leukocyte trafficking**

Leukocyte trafficking is a key feature of inflammation. In a mouse model, the irritant injection causes local infiltration, highlighting the role of cytokines in inflammation. A deficiency in chemotactic factors, specifically monocyte chemoattractant protein (MCP)-1, leads to a 50% decrease in IL-6 leukocyte infiltration.[50] It appears that the IL-6/sIL-6R complex stimulates MCP-1 production through trans-signaling, a process that enables IL-6 to activate cells that lack a conventional membrane-bound IL-6R. Although the addition of either IL-6 or sIL-6R alone was unable to induce MCP-1 production in endothelial cell cultures, the combination of the two produced a six- to sevenfold increase in MCP-1.[47]

- **Pannus**

Pannus is a defining characteristic of RA, contributing to joint destruction due to its invasive nature. Vascular endothelial growth factor (VEGF) is linked to pannus development, with TNF- and IL-1 affecting synovial cell VEGF production.[51] The VEGF level was significantly raised by the synergistic addition of the IL-6/sIL-6R complex. VEGF production was significantly reduced by IL-1 or TNF, but not by antibody to IL-6R.[51]

6.2. The systemic effect of IL-6 in RA

- **Acute-phase response**

The liver's primary stimulator of acute-phase protein production is IL-6; these proteins are frequently utilized in clinical practice as a biomarker of the severity of inflammation.[52] During Inflammation increases positive proteins like C-reactive protein, serum amyloid A, haptoglobin, and fibrinogen, while negative proteins like albumin and transferrin decrease. Fibrinogen is the primary component of the erythrocyte sedimentation rate.

- **Anemia**

RA patients frequently have anemia. Anemia in RA has several causes, including drug-induced anemia, anemia from a chronic illness, and active inflammation. Compared to people who are not anemic, patients with anemia frequently have more serious illnesses.[53] Anemia in RA is mostly due to IL-6. Hemoglobin levels fall in healthy animals after receiving an injection of IL-6.[54] It has been demonstrated that anemic patients have significantly higher IL-6 levels than nonanemic patients in RA patients.[55] IL-6 affects hemoglobin production of hepcidin by controlling iron metabolism in hepatocytes. Hepcidin deprives bone marrow of iron by reducing intestinal iron transport and inhibiting macrophage iron release.[56]

7. DIAGNOSIS OF RHEUMATOID ARTHRITIS

1. Clinically, RA patients ordinarily present with a new beginning of delicate and enlarged joints, morning joint firmness, and summed-up infection side effects, which are strange research center tests.[12]

2. RA is analyzed by a blend of the patient's side effects and the consequences of a specialist's assessment, evaluation of hazard factors following family ancestry, a joint appraisal by ultrasound sonography, and research facility markers like raised degrees of CRP and ESR in serum and recognition of RA-explicit autoantibodies.[18,57]

3. Ultrasound and magnetic resonance imaging (MRI) have both been suggested for diagnosing and

monitoring disease activity in RA patients.[58] Furthermore, ultrasonography can detect bone erosions[59], as well as subclinical synovitis, which can result in radiographic disease progression even when the patient appears to be in clinical remission.[60,61] Because of these qualities, ultrasonography is frequently utilized in clinical practice and clinical studies for RA diagnosis and disease monitoring.[62]

4. Ultrasonography offers cost-effective, widespread availability, and noninvasive real-time imaging, but requires extensive operator training for measurement and quality assessment.[62]

7.1. EC (EULAR CRITERIA) FOR THE DIAGNOSIS OF RA

The 2010 ACR-EULAR (American College of Rheumatology-European League against Rheumatism) criteria can also be used by physicians to diagnose[18,63,64] despite being primarily designed for the identification of homogeneous patient populations in clinical RA trials.[14,15] Thus, the 2010 EULAR models consolidate every one of the above-talked-about symptomatic boundaries exp. joint commitment, anomalies in CRP and ESR, presence of RA-explicit autoantibodies, and generally speaking marker period.

The 2010 EULAR standards were used to review joint contributions, focusing on 0-5 focuses, ACPAs, RF autoantibodies, CRP, expanded ESR, and infection signs. The review found that 82% of the criteria were considered, with 61% specificity. The study found that 82% of the criteria were met, indicating a high level of accuracy in detecting joint conditions.[63]

Table 1: The 2010 ACR was used to quantify clinical parameters used in the diagnosis of RA-EULAR. (Lin Y. J., "Update on the Path Mechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis", Lancet Lond. Engl.; 2020; 8th; 880-885).

Criteria		Points
Joint Involvement	1 large	0
	2-10 large	1
	1-3 Small	2
	4-10 Small	3
	>10 (at least 1 small)	5
Serology	Negative RF and ACPA	0
	Low Positive RF/ACPA	2
	High Positive RF/ACPA	3
Acute Phase Reactants	Normal CRP/ESR	0
	Abnormal CRP/ESR	1
		Σ= Overall Score

8. TREATMENT OF RHEUMATOID ARTHRITIS

When a patient is diagnosed with RA, the overall therapy goal is to achieve a complete remission or considerably decrease disease activity within 6 months to prevent joint deterioration, disability, and systemic symptoms of RA.[18,19] The Therapy should be initiated immediately and continually, with periodic appraisals of state illnesses and treatment plans. The standard treatment strategy for RA was based on a therapeutic pyramid, including bed rest, NSAID administration, and DMARD therapy if unsuccessful.[57] However, the success of this therapeutic technique was limited, as rheumatoid arthritis typically ended in joint degeneration, incapacity, inability to work, and increased mortality.[64]

Aspirin, diclofenac, and ibuprofen are examples of nonsteroidal anti-inflammatory drugs (NSAIDs) that relieve pain and swelling and improve joint function but are not disease-modifying since they do not prevent subsequent joint damage.[61] NSAIDs effectively reduce RA symptoms by suppressing proteinoid production through interactions with G-protein-coupled receptors. These second messengers, such as prostaglandins E2, PGD2, PGF, thromboxane A2, and prostacyclin, influence cellular activities. However, they are often linked to adverse effects in the renal, hepatic, gastrointestinal, and cardiovascular systems.[57]

8.1. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE TREATMENTOF RA

New pharmaceutical techniques enable effective disease management of RA, including disease- modifying antirheumatic medications (DMARDs). These medications treat symptoms, improve physical function, and slow joint degeneration progression. However, they should be used as supplementary therapy or short-term until a diagnosis is made.[57,65]

DMARDs are divided into manufactured and biologic specialists, with manufactured DMARDs being orally administered and biologic DMARDs being parenterally regulated. These treatments have been in clinical practice for over 50 years and focus on addressing poor people.[57] Synthetic DMARDs, developed using molecular and structural biology advancements, inhibit specific molecules like Janus kinases, preventing intracellular signal transduction particles that interpret cytokine impacts on cell reactions.[66] Methotrexate is the main which has been utilized in the treatment of RA for over

50 years, the ideal portion of 25 mg week after week was all the more asof late recognized.

8.2. SULFASALAZINE

Sulfasalazine (SSZ) was developed in 1938 for rheumatoid arthritis treatment, combining antibacterial and anti-inflammatory properties. It is effective, but its mechanism of action remains unknown. Studies have shown that SSZ impacts gut bacterial flora, inflammatory cell activities, and immunological processes. It can limit B-cell activity by inhibiting TNF-alpha production and decreasing inflammatory cytokine release. Additionally, it may increase adenosine synthesis at inflammation sites, similar to methotrexate.[67]

Sulfasalazine is typically continued perioperatively due to its short half-life of 4–5 hours and minimal immunosuppressive effect. Sulfasalazine can be stopped on the day of the operation to avoid a risk factor interaction or a potential additive hepatotoxic effect with medication taken before surgery.[67]

8.3. METHOTREXATE

Methotrexate is essential for several reasons. First, a considerable number of patients (25-40%) considerably improve with methotrexate monotherapy, which is paired with glucocorticoids approximately half of the patients can reach low disease activity in RA, a rate comparable to that attained with biological DMARDs in RA.[68,70] Second, its side effects are widely documented, such as nausea, hair loss, stoma itis, and hepatotoxicity, which can be avoided with prophylactic administration of folates (folic acid at 1 mg/d or 10 mg/k).[69] Third, targeted DMARDs are biologic and synthetic, and their effectiveness as monotherapies is lower than when coupled withmethotrexate.[71]

Anti-inflammatory properties of methotrexate are an analog of folic acid that interferes withthe activity of the dihydrofolate reductase, thereby both inhibiting nucleotide synthesis and purine metabolism. The action result is the production and release of adenosine, which was shown to havedirect anti-inflammatory properties.[71]

Additionally, methotrexate was to inhibit the binding of IL-1ß to the IL-1ßR, preventing IL- 1ß-induced inflammatory responses. Moreover, methotrexate was suggested to have effects on many other enzymes such as methyltransferases (which are important in both B- and T-cell function).[72]

8.4. BIOLOGIC DMARDS

When combined with methotrexate or other conservative synthetic DMARDs, all biologic and targeted synthetic DMARDs are more effective than when prescribed alone. However, IL-6 receptor antibody monotherapies (sarilumab, tocilizumab) and possibly also JAK inhibitors(baricitinib) have better clinical efficacy when combined with anti-TNF monotherapy (such as adalimumab).

8.5.1. TNF-A INHIBITORS

Joint inflammation and cartilage damage are effectively combated by neutralizing TNF- and inflammatory processes. TNF-A inhibitors are often used as second-line treatments when synthetic DMARD monotherapy fails. Infliximab, a chimeric mouse-anti-human IgG1 antibody, normalizes T-cell responses and hematological normalization while downregulating pro-inflammatory cytokine production. In clinical trials, it has shown potential in reducing inflammation and reducing inflammatory processes.[23]

8.5.2. IL-6 INHIBITORS, IL-6R INHIBITORS

The improvement of IL-6 blockers manages the cost of one more possibility for RA treatment. Thebinding of IL-6 to the soluble IL-6 receptor (SIL-6R), which then forms a trimer with two transmembrane glycoproteins (GP) 130 subunits, is the mechanism by which IL-6 triggers pro- inflammatory signaling. JAK activation and subsequent phosphorylation, homodimerization, and nuclear translocation of STAT-3 driving pro-inflammatory gene expression are both mediated by this compound of IL-6, SIL-6R, and two molecules of gp130.[62]

9. DEFINE CYTOKINES IN RHEUMATOID ARTHRITIS

9.1. TNF AND TNF- α IN RHEUMATOID ARTHRITIS

TNF is a focal cytokine in RA pathophysiology and watching shows a wide assortment of effectorcapabilities pertinent to the pathogenesis of RA and subsequently has a favorable to fiery impact at a few levels.[73,74] Synoviocyte survival and activation, cytokine and chemokine amplification, angiogenesis, and nociceptor activation are all sparked by TNF.[77] In societies of synovial cells from RA patients, the bar of TNF altogether diminishes the creation of other favorable to provocative cytokines and chemokines, like IL-1, IL-6, IL-8, or GM-CSF.[75] TNF quality unexpectedly creates provocative and damaging fringe joint inflammation portrayed by numeroussigns of RA (joint irritation, bone disintegration, and ligament annihilation).

Patients who failed traditional DMARDs are shifting to alternative TNF inhibitors as a third-line treatment. Shift inhibitors and abatacept are chosen as follow-up treatments due to their higher effectiveness in monotherapy studies.[76] The administration of a monoclonal anti-TNF antibody to these mice reduces illness progress.

TNF-α in 1985, animal sepsis models were used for the first preclinical studies utilizing antibodiesagainst TNF-α. Since then, antibodies against TNF-alpha have become an essential component of RA treatment and have transformed our patients' lives.[74]

Five anti-TNF medicines exist, each with different chemical structures, dosage regimes, and mechanisms of

action. Infliximab, the first TNF inhibitor approved for RA treatment in 2000, and Etanercept, a recombinant fusion protein complex, were authorized in 2000. Both therapies have increased risks of severe infections, including bacterial infections like pneumonia, herpes zoster, tuberculosis, and opportunistic infections.[75]

A recombinant human IgG1 monoclonal antibody has a high affinity for soluble and membrane-bound TNF-α. Subcutaneous injections are used to administer it once every two weeks. Human IgG1 monoclonal antibody Golimumab (GOL) neutralizes both soluble and membrane- bound TNF-α.[76]

9.2. INTERLEUKIN-1

Several innate immune processes and regulated inflammation are masterly regulated by IL-1.[80] IL-1, a leukocyte pyrogen, has multiple biological roles. It was discovered as a macrophage- derived immune system mediator acting on T and B lymphocytes and was later named IL-1 by the Second International Lymphokine Workshop in 1979. LAF induces multiple components in the acute phase response and regulates serum adhesion-promoting factors in breast cancer patients.[78]

9.3. INTERLEUKIN-17

The pro-inflammatory cytokines IL-17A and IL-17F, which are collectively referred to as IL-17, are hallmarks of CD4+ T helper 17 (Th17) cells. They transmit signals via a heterodimeric receptor complex made up of the IL-17 receptors IL-17RA and IL-17RC and function as homodimers or heterodimers.[79] It is a crucial role in protecting against bacterial and parasitic contaminations, but its creation or flagging can cause inflammation and tissue obliteration. Eculizumab, a killing immunizer against IL-17A, has been approved by the US Food and Drug Administration due to its effectiveness in treating moderate to severe psoriasis.

Dysregulated IL-17 is a significant pathogenic factor in cancer development, inhibiting tumorigenesis in various organs. Validation in independent coho could benefit IL-17A polymorphisms linked to cancer susceptibility.[80]

9.4. INTERLEUKIN-10

Mossman discovered IL-10 in 1989, an anti-inflammatory cytokine, which is a significant negative factor in inflammatory diseases, particularly IBD, due to its loss.[55] The IL-10 family of cytokines includes IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, and its more distantly related IL-28A, IL-28B, and IL-29.[81] IL-10 is the founding member of the IL-10 family. Synthetic inhibitory factor (CSIF) produced by inhibitory Th2 T cell clones Production of multiple cytokines from Th1 cells was the original description of IL-10.[82]

IL-10 forms a non-covalent homodimer with IL-10R1 and IL-10R2 receptor chains, with IL-10R1 being the only highly affinity-bound component. Other receptors include IL-22, IL-26, IL-28A, IL-28B, and IL-29.[82]

This section discusses IL-10's characteristics, molecular signals, and advances in therapeutic manipulation of IL-10 in various cells, including surprising discoveries and advancesin therapeutic manipulation.[83]

9.5. GM-CSF

The pro-inflammatory cytokine GM-CSF is known to function at the innate-innate junction. The immunity develops over time. GM-CSF levels in synovial cells are increased in several investigations. An RA patient's body fluids, plasma, and overexpressed GM-CSF receptor (GM- CSFR) Synovial tissue from RA patients.[83] GM-CSF or GM-CSFR were produced and analyzed. Mavrilimumab (CAM-3001), a monoclonal antibody against the GM-CSFR alpha chain, enhanced ACR50 responses in clinical studies compared to placebo. Clinical preliminaries showed a significant difference (30.8% mavrilimumab versus 12.0% fake treatment at week 12), while sarilumab, denosumab, and ramucirumab were adapted IgG1 monoclonal antibodies focusing on GM-CSF.[84]

CONCLUSION

The discovery of a wide range of reagents that target Interleukin-6, Interleukin-1, Interleukin-10, Interleukin-17, Tumor necrosis factor, and Granulocyte-macrophage colony-stimulating factor evidence enough to suggest that the ideal treatment for rheumatoid arthritis has not yet been discovered. Patients have been treated with a variety of DMARDs and IL-6 antagonists, resulting in some interesting outcomes: The patients' signs and symptoms of life improved, further demonstrating that Interleukin-6 plays a crucial role in RA pathogenesis. TNF and IL-6-induced osteoclasts may contribute to the pathophysiology of inflammatory arthritis linked with joint deterioration, such as RA, according to our findings.

REFERENCES

1. Cross M., Smith E., Hoy D., “The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study”, *Ann Rheum Dis*., 2014; 73(7): 1316–1322.
2. McInnes I. B., Schett G., “The pathogenesis of rheumatoid arthritis”, *N Engl J Med*., 2011; 365(23): 2205–2219.
3. Heiberg T, Finset A., Uhlig T., Kvien T. K., “Seven-year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis”, *Ann Rheum Dis*., 2005; 64(2): 191–195.
4. Heiberg T., Kvien T. K., “Preferences for improved health examined in 1024 patients with rheumatoid arthritis: pain has highest priority”, *Arthritis Rheum*, 2002; 47(4): 391–397.
5. Hirano T., “Interleukin-6 in autoimmune and inflammatory diseases”, a personal memoir. Proceedings of the Japan Academy, Series B, 2014; 90(6): 183–195.
6. Bas D. B., Su J., Wigerblad G., Svensson C. I., “Pain in rheumatoid arthritis”, models and

mechanisms. *Pain Manag*, 2016; 6(3): 265–284.
7. Choy E. H. S., Calabrese L. H., "Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis", *Rheumatology (Oxford)*, 2018; 57(11): 1885–1895.
8. Zhou Y. Q., Liu Z., Liu Z., "Interleukin-6: an emerging regulator of pathological pain", *J Neuroinflammation*, 2016; 13(1): 141.
9. McInnes I. B., & Schett G., "Cytokines in the pathogenesis of rheumatoid arthritis", Nature Reviews Immunology; 2011; 7(6): 429-442.
10. Yokota K., Miyazaki T., & Hirano T., "The Role of Interleukin-6 in Pathophysiology of Rheumatoid Arthritis", International Journal of Rheumatology; 5th edition, 2014; 1-11.
11. Smolen J. S., "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs", 2019 update. Annals of the Rheumatic Diseases, 2018; 79(6): 685-699.
12. Smolen J. S., Aletaha D., McInnes I. B., "Rheumatoid arthritis" Lancet Lond Engl; 388th edition, 2016; 2023–2038.
13. Littlejoh E. A., Monrad S., "Early Diagnosis, and Treatment of Rheumatoid Arthritis" Prim. Care: Clin. O. Pr.; 45th edition, 2018; 237–255.
14. Sacks J. J., Luo Y. H., Helmick C. G., "Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States", Arthritis Rheum; 62nd edition, 2010; 460–464.
15. Myasoedova E., Crowson C. S., Kremers H.M., Therneau T.M., Gabriel S.E., "Is the incidence of rheumatoid arthritis rising", Results from Olmsted County, Minnesota, 1955–2007; Arthritis Rheum, 62nd edition, 2010; 1576–1582.
16. Brzustewicz E., Hence I., Daca A., Szarecka M., Sochocka-Bykowska M., Witkowski J., Bryl E., "autoantibodies C-reactive protein, erythrocyte sedimentation rate, and serum cytokine profiling in of monitoring early treatment", Cent. Eur. J. Immunol; 42nd edition, 2017; 259– 268.
17. Aletaha D., Ramiro S., "Diagnosis and Management of Rheumatoid Arthritis", JAMA; 320th edition, 2018; 1360–1372.
18. Sangha O., "Epidemiology of rheumatic diseases", Rheumatology; 39th edition, 2000; 3–12.
19. McInnes I. B., Schett G., "Cytokines in the pathogenesis of rheumatoid arthritis", Nat Rev Immunol; 7th edition, 2007; 429–442.
20. Choy E.H., Kavanaugh A. F., Jones S. A., "The problem of choice: current biologic agents and prospects in RA", Nat Rev Rheumatol; 9th edition, 2013; 154–163.
21. Zhang F, McInnes I. B., Schett G., "To the Cytokines in the pathogenesis of rheumatoid arthritis in interleukin-6", Nat. Rev. Immunol; 8th edition, 2013; 454- 434.
22. Kalliolias G. D., Ivashkiv L. B., "TNF biology, pathogenic mechanisms, and emerging therapeutic strategies", Nat. Rev. Rheumatol, 2016; 169.
23. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., "Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin", Nature; 324th edition, 1986; 73–6.
24. Kang S., Narazaki M., Metwally H., Kishimoto T., "Historical overview of the interleukin-6 family cytokine", J. Exp. Med; 217th edition, 2020; 347.
25. Mihara M., Hashizume M., Yoshida H., Suzuki M., Shiina M., "IL-6/IL-6 receptor system and its role in physiological and pathological conditions" Clin Sci; 122nd edition, 2012; 143–59.
26. Lipsky P. E., "Interleukin-6 and rheumatic diseases", Arthritis Res Ther; 8th edition, 2006; 4.
27. Hunter C. A., Jones S.A, "IL-6 is a keystone cytokine in health and disease", Nat Immunol; 16th edition, 2015; 448-54.
28. Kotake S., Sato K., Kim K. J., "Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation", J Bone Miner Res; 11th edition, 1996; 88–95.
29. Chabaud M., Durand J. M., Buchs N., "Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium", Arthritis Rheum; 42nd edition, 1999; 963–70.
30. Bastard J. P., Maachi M., Lagathu C., Kim M. J., Caron M., Vidal H., "Recent advances in the relationship between obesity, inflammation, and insulin resistance," Eur Cytokine Netw, 2006; 174–12.
31. Kishimoto T., Akira S., Taga T., "Interleukin-6 and its receptor: a paradigm for cytokines", Sciences, 258th edition, 1992; 593–7.
32. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T., "Molecular cloning and expression of an IL-6 signal transducer, gp130 Cell", 63rd edition, 1990; 1149–57.
33. Hunter C. A., Jones S. A., "IL-6 is a keystone cytokine in health and disease," Nat Immunol, 2015; 16: 448–57.
34. Rose-John S., Winthrop K., Calabrese L., "The role of IL-6 in host defense against infections: immunobiology and clinical implications," Nat Rev Rheumatol, 2017; 13: 399–409.
35. Schaper F., Rose-John S., "Interleukin-6: Biology, signaling, and strategies of the blockade," Cytokine Growth Factor Rev., 2015; 26: 475–87.
36. Mullberg J., Schooltink H., Stoyan T., "The soluble interleukin-6 receptor is generated by shedding," Eur J Immunol, 1993; 23: 473–80.
37. Heink S., Yogev N., Garbers C., "Trans-presentation of IL-6 by dendritic cells is required for priming pathogenic TH17 cells," Nat Immunol, 2017; 18: 74–85.
38. Hibi M., Murakami M., Saito M., Hirano T., Taga T., and Kishimoto T., "Molecular cloning and expression of an IL-6 signal transducer, gp130," Cell, 1990; 63(6): 1149–1157.

39. Lutticken C., Wegenka U. M., Yuan J., "Association of transcription factor APRF and proteinkinase Jak1 with the interleukin-6 signal transducer gp130," Science, 1994; 263: 5143;89–92.
40. Taga T., Hibi M., Hirata Y., "Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130," Cell, 1989; 58(3): 573–581.
41. Stahl N., Boulton T. G., Farruggella T., "Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components," Science, 1994; 263: 5143, 92–95.
42. Rose-John S., "IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro- inflammatory activities of IL-6," International Journal of Biological Sciences, 2012; 8(9): 1237–1247.
43. Akira S., Nishio Y., Inoue M., "Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway," Cell, 1994; 77(1): 63–71.
44. Stahl N., Farruggella T. J., Boulton T. G., Zhong Z., Darnell J. E., and Yancopoulos G. D., "Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokinereceptors," Science, 1995; 267(5202): 1349–1353.
45. Tomida M., Heike T., and Yokota T., "Cytoplasmic domains of the leukemia inhibitory factor receptor required for STAT3 activation, differentiation, and growth arrest of myeloid leukemic cells," Blood, 1999; 93(6): 1934–1941.
46. Madhok R., Crilly A., Watson J., Capell H. A., "Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity", Ann Rheum Dis; 1993; 52; 232– 234.
47. Uson J., Balsa A., Pascual-Salcedo D., "Soluble interleukin 6 (IL-6) receptor and IL-6 levelsin serum and synovial fluid of patients with different arthropathies," J Rheumatol, 1997; 24: 2069– 2075.
48. Kotake S., Sato K., Kim K. J., "Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation," J Bone Miner Res., 1996; 11: 88– 95.
49. Brozik M., Rosztoczy I., Meretey K., "Interleukin 6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production," J Rheumatol, 1992; 19: 63– 68.
50. Romano M., Sironi M., Toniatti C., "Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment," Immunity, 1997; 6: 315– 325.
51. Lally F., Smith E., Filer A., "A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium," Arthritis Rheum, 2005; 52: 3460– 3469.
52. Gabay C., Kushner I., "Acute-phase proteins and other systemic responses to inflammation," N Engl J Med., 1999; 340: 448– 454.
53. Han C., Rahman M. U., Doyle M. K., "Association of anemia and physical disability among patients with rheumatoid arthritis," J Rheumatol, 2007; 34: 2177– 2182.
54. Jongen-Lavrencic M., Peeters H. R., Rozemuller H., "IL-6-induced anemia in rats: possible pathogenetic implications for anemia observed in chronic inflammations," Clin Exp Immunol, 1996; 103: 328– 334.
55. Voulgari P. V., Kolios G., Papadopoulos G. K., "Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis," Clin Immunol, 1999; 92: 153– 160.
56. Nemeth E., Tuttle M. S., Powelson J., "Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization," Science, 2004; 306: 2090–2093.
57. Burmester G., Pope J. E., "Novel treatment strategies in rheumatoid arthritis", Lancet; 389th edition, 2017; 2338–2348.
58. D'Agostino M. A., Terslev L., Wakefield R., Østergard M., Balint P., Naredo E., Iagnocco A., Backhaus M., Grassi W., Emery P., "Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis", From diagnosis to remission. Ann. Rheum; 75th edition, 2016; 1902–1908.
59. Zayat A. S., Ellegaard K., Conaghan P. G., Terslev L., Hensor E. M. A., Freeston J., Emery P., Wakefield R. J., "The specificity of ultrasound-detected bone erosions for rheumatoid arthritis", Ann. Rheum. Dis.; 74th edition, 2014; 897–903.
60. Yoshimi R., Hama M., Takase K., Iwata A., Kishimoto D., Terauchi K., Watanabe R., UeharaT., Samukawa S., Ueda A., "Ultrasonography is a potent tool for the prediction of progressivejoint destruction during clinical remission of rheumatoid arthritis", Mod. Rheumatol; 23rd edition, 2013; 456–465.
61. Iwamoto T., Ikeda K., Hosokawa J., Yamagata M., Tanaka S., Norimoto A., Sanayama Y., Nakagomi D., Takahashi K., Hirose K., "Prediction of Relapse after Discontinuation of Biologic Agents by Ultrasonographic Assessment in Patients With Rheumatoid Arthritis in Clinical Remission", High Predictive Values of Total Gray-Scale and Power Doppler Scores That Represent Residual Synovial Arthritis Rheum; 66th edition, 2014; 1576–1581.
62. Minegishi K., Horita N., Kobayashi K., Yoshimi R., Kirino Y., Ohno S., Kaneko T., Nakajima H., Wakefield R.J., Emery P., "Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis", Systematic review and meta-analysis Rheumatology; 57th edition, 2017; 49–58.
63. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D., Bingham C.O., Birnbaum N.S., Burmester G., Bykerk V., Cohen M.D., "Rheumatoid arthritis classification criteria, An American College of Rheumatology", European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis; 69th edition, 2010; 1580–1588.

64. Radner H., Neogi T., Smolen J.S., Aletaha D., "Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis", A systematic literature review. Ann. Rheum. Dis; 73rd edition, 2013; 114–123.
65. Fries J., "Current treatment paradigms in rheumatoid arthritis", Rheumatology; 39th edition, 2000; 30–35.
66. Smolen J.S., Vander H. D., Machold K.P., Aletaha D., Landewé R., "Proposal for a new nomenclature of disease-modifying antirheumatic drugs", Ann Rheum Dis.; 73rd edition, 2014; 3-5.
67. Smedegård G., Björk J., "Sulphasalazine: Mechanism of Action in Rheumatoid Arthritis", Rheumatology; 34th edition, 1995; 7–15.
68. Emery P., Bingham C. O., Burmester G. R., "Certolizumab pegol in combination with dose-optimized methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomized, double-blind, placebo-controlled phase III study", Ann Rheum Dis; 76th edition, 2017; 96-104.
69. Vanede A.E., Laan R.F., Rood M.J., "Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study", Arthritis Rheum; 44thedition, 2001; 1515-1524.
70. Nam J.L., Villeneuve E., Hensor E.M., "Remission induction comparing infliximab and high- dose intravenous steroid, followed by treat-to-target: a double-blind, randomized, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)", Ann Rheum Dis; 73rd edition, 2014; 75-85.
71. Cronstein B. N., Naime D., Ostad E., "The anti-inflammatory mechanism of methotrexate", Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Investing; 92nd edition, 1993; 2675–2682.
72. Wennerstrand P., Mårtensson L. G., Söderhäll S., Zimdahl A., Appell M. L., "Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high- dose infusions in childhood leukemia", Eur. J. Clin. Pharmacol.; 69th edition, 2013; 1641– 1649.
73. Brennan F. M., "McInnes IB Evidence that cytokines play a role in rheumatoid arthritis", J Clin Invest; 118th edition, 2008; 3537–3545.
74. Kalliolias G. D., Ivashkiv L. B, "TNF biology, pathogenic mechanisms, and emerging therapeutic strategies", Nat Rev Rheumatol; 12th edition, 2018; 49–62.
75. Brennan F. M., Chantry D., Jackson A., Maini R., Feldmann M., "Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis", Lancet; 2nd edition, 1989; 244– 247.
76. Smolen J. S., Burmester G. R., Combe B., "Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis", 2-year efficacy and safety results from the randomized EXXELERATE study Lancet; 388th edition, 2016; 2763–74.
77. Heiberg T, Finset A., Uhlig T., Kvien T. K., "Seven-year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis", *Ann Rheum Dis*, 2005; 64(2): 191–195.
78. Allavena P., Sica A., Solinas G., Porta C., Mantovani A., "The inflammatory microenvironment in tumor progression the role of tumor-associated macrophages", Crit Rev Oncol Hematol; 66th edition, 2008; 1–9.
79. Chang S. H., Dong C., "A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses", Cell Res; 17th edition, 2007; 435–440.
80. Punt S., Langenhoff J. M., Putter H., Fleuren G. J, Gorter A., Jordanova E. S., "The correlationsbetween IL-17 vs. Th17 cells and cancer patient survival", systematic review Onco- Immunology; 4th edition, 2015; 98-454.
81. Ouyang W., "Regulation and functions of the IL-10 family of cytokines in inflammation and disease" Annu Rev Immunol; 29th edition, 2011; 71–109.
82. Rutz S., Wang X., Ouyang W., "The IL-20 subfamily of cytokines – from host defense to tissue homeostasis", Nat Rev Immunol; 14th edition, 2014; 783–95.
83. Firestein G. S., Taetle R., Kaushansky K., Zvaifler N. J., "Cytokines in chronic inflammatory arthritis Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions", J. Clin. Investig; 83rd edition, 1989; 876–882.
84. Roelofs M. F., Boelens W. C., Joosten L., Abdollahi-Roodsaz S., Geurts J., Wunderink L. U., Schreurs B. W., Berg, "W.B.V.D.; Radstake, T.R.D.J. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis", J. Immunol; 176th edition, 2006; 7021–7027.